Merger expands OncoC4’s wholly owned immunotherapy pipeline and establishes in-house clinical manufacturing capabilities ...

LONDON, UK I4, 2024 I Duke Street Bio Ltd, a precision medicine biotech developing next generation small molecule cancer therapies, is pleased to ...

Innovative, Nature-inspired Mechanism, Dissolving Blood Clots Without Inducing Bleeding, Shows Promises of Enhanced Safety and Efficacy ...

Kisunla™ (donanemab-azbt), pronounced kih-SUHN-lah, is used to treat adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of ...

TOKYO, Japan I5, 2024 I Kyowa Kirin Co., Ltd. (Kyowa Kirin) (TSE:4151) (President and CEO: Masashi Miyamoto) announced top-line results of the ...

ATLANTA, GA, USA I5, 2024 I UCB, a global biopharmaceutical company, today announced the presentation of new four-year data in patients with ...

Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration ...

Metsera plans to initiate a Phase 2b trial of MET-097 in Q4 2024, with data anticipated in the first half of 2025.

NEW HAVEN, CT, USA I3, 2024 I Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), today announced positive topline results from ...

LONDON, UK I3, 2024 I Vicebio Ltd ("Vicebio"), a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral ...

In preclinical studies ARO-INHBE reduced body weight and fat mass with a novel mechanism of action that may preserve lean muscle mass compared to currently ...

SYDNEY, Australia I September 23, 2024 I Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the ...